MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Altimmune Inc

Cerrado

4.43 -6.34

Resumen

Variación precio

24h

Actual

Mínimo

4.35

Máximo

4.73

Métricas clave

By Trading Economics

Ingresos

3.6M

-20M

Ventas

5K

BPA

-0.26

Margen de beneficio

-391,500

Empleados

59

EBITDA

2.9M

-20M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+370.17% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-149M

314M

Apertura anterior

10.77

Cierre anterior

4.43

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Altimmune Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 jul 2025, 15:29 UTC

Principales Movimientos del Mercado

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7 jul 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7 jul 2025, 23:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 jul 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7 jul 2025, 23:19 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 jul 2025, 23:19 UTC

Charlas de Mercado

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7 jul 2025, 22:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 jul 2025, 22:20 UTC

Charlas de Mercado

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7 jul 2025, 21:34 UTC

Adquisiciones, fusiones, absorciones

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 jul 2025, 20:45 UTC

Adquisiciones, fusiones, absorciones

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 jul 2025, 20:16 UTC

Charlas de Mercado

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7 jul 2025, 19:37 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7 jul 2025, 19:12 UTC

Charlas de Mercado

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7 jul 2025, 18:33 UTC

Charlas de Mercado

Gold Flat as Investors Assess Market Direction -- Market Talk

7 jul 2025, 18:27 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 jul 2025, 16:53 UTC

Ganancias

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7 jul 2025, 16:30 UTC

Charlas de Mercado

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 jul 2025, 16:05 UTC

Adquisiciones, fusiones, absorciones

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 jul 2025, 15:41 UTC

Charlas de Mercado

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7 jul 2025, 15:41 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 jul 2025, 15:40 UTC

Charlas de Mercado

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7 jul 2025, 15:30 UTC

Charlas de Mercado

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7 jul 2025, 15:18 UTC

Charlas de Mercado

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7 jul 2025, 15:14 UTC

Adquisiciones, fusiones, absorciones

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7 jul 2025, 15:00 UTC

Adquisiciones, fusiones, absorciones

GSK Completes Acquisition of Efimosfermin

7 jul 2025, 14:52 UTC

Charlas de Mercado

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7 jul 2025, 14:51 UTC

Charlas de Mercado

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7 jul 2025, 14:45 UTC

Charlas de Mercado

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Comparación entre iguales

Cambio de precio

Altimmune Inc Esperado

Precio Objetivo

By TipRanks

370.17% repunte

Estimación a 12 meses

Media 22.38 USD  370.17%

Máximo 28 USD

Mínimo 12 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Altimmune Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

5.365 / 6.0486Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.